Masavibart (ZRC3308-A7) is a monoclonal antibody of the IgG1 subtype, specifically designed to target SARS-CoV-2. This antibody exhibits strong binding affinity to a distinct, non-competing epitope located on the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein. For enhanced therapeutic efficacy, Masavibart can be co-administered with ZRC3308-B10 in a 1:1 ratio. This combination has shown potential in the prevention of COVID-19, particularly effective in the initial stages of the disease, prior to the onset of severe symptoms.
Masavibart (ZRC3308-A7) is a monoclonal antibody of the IgG1 subtype, specifically designed to target SARS-CoV-2. This antibody exhibits strong binding affinity to a distinct, non-competing epitope located on the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein. For enhanced therapeutic efficacy, Masavibart can be co-administered with ZRC3308-B10 in a 1:1 ratio. This combination has shown potential in the prevention of COVID-19, particularly effective in the initial stages of the disease, prior to the onset of severe symptoms.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
